On Sept. 21, 2020, XBiotech announced it was developing a new breakthrough candidate therapy it calls FLUVID for treating illness caused by combined infections with influenza and COVID-19.

FLUVID therapy will combine XBiotech’s breakthrough influenza True Human antibodies together with its recently discovered COVID-19 antibodies into one treatment.

FLUVID is the culmination of years of research and development. It incorporates extraordinary influenza antibodies that target all known strains of influenza, combined with the Company’s recently discovered COVID-19 antibody, passive immunity derived from patients who recovered rapidly from the virus without serious illness.

FLUVID harnesses the best in human immunity to provide what is expected to be a safe and effective therapy against both deadly viruses.